Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Molecular Shapes

Molecular Shapes

Molecules have characteristic shapes that are crucial for their function. The arrangement of various electron groups around the central atom dictates their molecular geometry. Electron pairs in the valence shell of a central atom will adopt an arrangement that minimizes repulsions between the electron pairs by maximizing the distance between them. The valence electrons form either bonding pairs, located primarily between bonded atoms, or lone pairs.Two regions of electron density in a diatomic...

Molecular Models

Molecular Models

Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.

Molecular Orbital Theory I

Molecular Orbital Theory I

Overview of Molecular Orbital Theory

VSEPR Theory and the Basic Shapes

VSEPR Theory and the Basic Shapes

Overview of VSEPR Theory

Predicting Molecular Geometry

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

European urology oncology·2026

Same author

Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study).

European urology oncology·2026

Same author

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.

European urology·2026

Same author

European Study of Prostate Cancer Screening - 23-Year Follow-up.

The New England journal of medicine·2025

Same author

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

The New England journal of medicine·2025

Same author

Re: quantifying Gleason pattern 4: the multifocality blind spot in prognostic models.

BJU international·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

[Molecular forms of PSA].

Amine Benchikh El Fegoun¹, Arnauld Villers

¹Service d'urologie, CHRU Lille, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie

|May 11, 2007

Summary

Molecular forms of prostate-specific antigen (PSA) are being developed to enhance prostate cancer diagnosis. While free PSA (f/t PSA) offers some specificity, newer forms like proPSA show limited ability to distinguish cancer from benign prostatic hyperplasia (BPH).

Area of Science:

Biochemistry and Molecular Biology
Oncology
Urology

Context:

Serum prostate-specific antigen (PSA) is a key biomarker for prostate cancer diagnosis and staging.
Total PSA (tPSA) exists in bound (complexed PSA, cPSA) and unbound (free PSA, fPSA) molecular forms.
Evaluating these molecular forms and their ratios (f/t PSA, c/t PSA) aims to improve diagnostic accuracy.

Purpose:

To assess the diagnostic utility of different molecular forms of PSA in distinguishing prostate cancer from benign prostatic hyperplasia (BPH).
To evaluate the clinical performance of free PSA (fPSA) and complexed PSA (cPSA) as diagnostic markers.
To explore novel PSA derivatives like proPSA, intact PSA, human Kallikrein 2, and BPSA for improved specificity.

Summary:

Free PSA (fPSA) percentage is more specific but less sensitive than tPSA, making it a potential second-line test after negative biopsies.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Experiment Videos

Last Updated: Jul 15, 2026

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Complexed PSA (cPSA) demonstrates higher specificity than tPSA in the diagnostic gray zone (2-10 ng/ml) at high sensitivity.

Emerging PSA derivatives, including proPSA and BPSA, have not yet demonstrated a clear ability to differentiate cancer from BPH or establish reliable cutoff values.

Impact:

Current molecular PSA forms offer incremental improvements in specificity, particularly in the gray zone, but widespread adoption is limited by modest gains and established tPSA use.
Further research into novel PSA derivatives is needed to identify markers with superior discriminatory power between prostate cancer and BPH.
Development of refined PSA assays could lead to more accurate prostate cancer diagnosis, potentially reducing unnecessary biopsies and improving patient management.